TY - JOUR T1 - IL-21, inflammatory cytokines and hyper polarized CD8<sup>+</sup> T cells are central players in Lupus immune pathology JF - medRxiv DO - 10.1101/2022.10.18.22281177 SP - 2022.10.18.22281177 AU - Soumya Sengupta AU - Gargee Bhattacharya AU - Subhasmita Mohanty AU - Shubham K Shaw AU - Gajendra M Jogdand AU - Rohila Jha AU - Prakash K Barik AU - Jyoti R Parida AU - Satish Devadas Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/10/20/2022.10.18.22281177.abstract N2 - Systemic Lupus Erythematous (SLE) is a chronic autoimmune disorder, broadly characterized by systemic inflammation along with heterogeneous clinical manifestations, severe morbidity, moribund organ failure and eventual mortality. In our study, SLE patients displayed higher percentage of activated, inflamed and hyper polarized CD8+ T cells, dysregulated CD8+ T cell differentiation, significantly elevated serum inflammatory cytokines, higher accumulation of cellular ROS when compared to healthy controls. Importantly, these hyper inflammatory/hyper polarized CD8+ T cells responded better to an anti-oxidant than to an oxidant. Terminally differentiated Tc1 cells also showed plasticity upon Oxidant/antioxidant treatment but was in contrast to the SLE CD8+ T cell response. Our studies suggest that the differential phenotype and redox response of SLE CD8+ T cells and Tc1 cells could be attributed to their cytokine environs during their respective differentiation and eventual activation environs. Polarisation of Tc1 cells with IL-21 drove hyper cytoxicity without hyper polarisation suggesting that SLE inflammatory environment could drive the extreme aberrancy in SLE CD8+ T cell.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the core funding of Institute of Life Sciences, Bhubaneswar, Department of Biotechnology, Government of India. SS was funded by the DBT fellowship. GB, and SKS were funded by the CSIR fellowship. RJ was funded by institutional fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies involving human participants were reviewed and approved by the Institutional Human Ethics Committee, Institute of Life Sciences. The Institutional Ethics Committee (IEC)/ Institutional Review Board (IRB) reference number is 74/HEC/18. Written consent informed to participate in this study was provided by the participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the relevant data are given in the manuscript/ supplementary materials. ER -